文献速递真菌感染

T2MR念珠菌检测板能否替代SeptiFast用于常规临床实践中念珠菌血症的快速诊断

Is the T2MR Candida Panel a suitable alternative to the SeptiFast for the rapid diagnosis of candidemia in routine clinical practice?
PubMed 文献 · Clin Microbiol Infect · 2024-03-01

研究分析了2018年8月至2020年4月138例疑似念珠菌血症ICU患者的177份血样本,同步进行血培养、SeptiFast和T2Candida检测。确诊念珠菌血症22份样本中,血培养和SeptiFast灵敏度均为68.2%,T2为63.6%;确诊加很可能念珠菌血症中,血培养灵敏度40.5%,SeptiFast为81.1%,T2为73.0%。作者认为T2与SeptiFast诊断性能相似,可替代已不可用的SeptiFast。

要点

  • 确诊念珠菌血症样本中,血培养和SeptiFast灵敏度均为68.2%,T2为63.6%。
  • 确诊加很可能念珠菌血症中,SeptiFast灵敏度81.1%,T2为73.0%,血培养为40.5%。
  • 作者认为T2与SeptiFast诊断性能相似,可替代已不可用的SeptiFast。

核心结论

  • SeptiFast与T2Candida诊断性能相似,在确诊/很可能念珠菌血症样本中两者灵敏度均高于血培养。
  • 作者认为T2可替代已不可用的SeptiFast用于念珠菌血症诊断,并与其他诊断方法联合使用,以便及时启动目标抗真菌治疗。

研究设计与样本

  • 研究于2018年8月至2020年4月收集疑似念珠菌血症的高危重症监护病房患者的血样本,共177份样本来自138例患者。
  • 血样本同步进行血培养、SeptiFast和T2Candida检测,随后根据临床和微生物学结果将样本分为确诊、很可能和无念珠菌血症三类。

主要发现

  • 22份样本来自17例患者被分类为确诊念珠菌血症,15份样本来自14例患者被分类为很可能念珠菌血症。
  • 仅评估确诊念珠菌血症时,血培养灵敏度68.2%(95% CI,45-86%),SeptiFast灵敏度68.2%(95% CI,45-86%),T2灵敏度63.6%(95% CI,41-83%)。
  • 评估确诊和很可能念珠菌血症时,血培养灵敏度40.5%(95% CI,23-58%),SeptiFast灵敏度81.1%(95% CI,65-92%),T2灵敏度73.0%(95% CI,56-86%)。

关键数值与推荐

  • 确诊念珠菌血症:血培养灵敏度68.2%(95% CI,45-86%),SeptiFast灵敏度68.2%(95% CI,45-86%),T2灵敏度63.6%(95% CI,41-83%)。
  • 确诊加很可能念珠菌血症:血培养灵敏度40.5%(95% CI,23-58%),SeptiFast灵敏度81.1%(95% CI,65-92%),T2灵敏度73.0%(95% CI,56-86%)。

临床怎么用

  • 作者认为T2可替代已不可用的SeptiFast用于念珠菌血症诊断,并与其他诊断方法联合使用,以便及时启动目标抗真菌治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The diagnosis of invasive Candida infection remains challenging because of tests with slow turnaround times or mediocre performance. T2magnetic resonance imaging is a new diagnostic tool. We investigated the diagnostic accuracy of the T2Candida panel (T2) in comparison with blood culture (BC) and the SeptiFast (SF) for the detection of five different Candida species among high-risk intensive care unit patients with suspected candidemia. METHODS: We analysed blood samples collected from patients with suspected candidemia (177 samples from 138 patients) from August 2018 to April 2020. Blood samples were collected and analysed concurrently by BC, SF, and T2Candida. Subsequently, based on clinical and microbiological findings, patient samples were assigned to specific risk categories (proven, probable, and no candidemia). RESULTS: Twenty-two samples from 17 patients were classified as proven candidemia, and 15 samples from 14 patients were classified as probable candidemia. A sensitivity of 68.2% (95% CI, 45-86%) was observed for the BC and the SF, and a sensitivity of 63.6% (95% CI, 41-83%) was observed for the T2 when only cases with proven candidemia were evaluated. For proven and probable candidemia, the sensitivity was 40.5% (95% CI, 23-58%) for BC, 81.1% (95% CI, 65-92%) for SF, and 73.0% (95% CI, 56-86%) for T2. DISCUSSION: The diagnostic performance of SF and T2 was similar. For samples with proven/probable candidemia, SF and T2 had a higher sensitivity compared to BC. Used in conjunction with other diagnostic methods, T2 can replace the no longer available SF for the diagnosis of candidemia, enabling the timely initiation of targeted antifungal therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Camp I, Füszl A, Selitsch B, et al. Is the T2MR Candida Panel a suitable alternative to the SeptiFast for the rapid diagnosis of candidemia in routine clinical practice? Clin Microbiol Infect. 2024. PMID: 38432432. doi:10.1016/j.cmi.2024.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。